Survodutide: What Do Its Weight-Loss Trials Tell Us?

Understanding the survodutide findings

Survodutide has now been studied in phase 3 weight-loss trials. It is still being developed and is not offered by The Care Pharmacy. Here is what the results tell us about weight loss, side effects and heart safety, including how many people stopped treatment.

Survodutide research guide: a woman in a quiet town square, with The Care Pharmacy branding

What is survodutide?

Survodutide is an investigational medicine being developed by Boehringer Ingelheim with Zealand Pharma. It is being studied as a weekly injection for obesity and related metabolic conditions. BI 456906 is its development code.

It activates receptors for two hormones: glucagon and GLP-1. Researchers are interested in how this combination affects appetite, energy use and metabolic health. It is different from semaglutide and tirzepatide, even though some of the hormone terminology sounds familiar.

The Care Pharmacy does not offer survodutide. Published trial results can tell us about the treatment being studied, but they do not make it a medicine that can be ordered through our website.

The most useful questions are how much benefit was seen, how often side effects occurred and how many people could continue treatment. Those details give a fuller picture than the largest weight-loss figure in a headline.

What did the survodutide obesity trial find?

The phase 3 SYNCHRONIZE-1 trial studied 725 adults with obesity or overweight and a related complication, without diabetes. They received survodutide or placebo, alongside lifestyle counselling, for 76 weeks.

In an analysis that included people who stopped or paused treatment, average weight loss was 12.2% and 13.0% in the two survodutide groups, compared with 5.4% with placebo.

Other analyses may produce different figures because they ask what would happen if people stayed on the assigned treatment. That distinction matters. A medicine’s effect when taken consistently and the results across everyone assigned to it are related, but different, questions.

Some older reports also quote results from the earlier phase 2 study. They should not be labelled as the phase 3 result. The study name, duration and analysis need to stay attached to the number.

For an individual, none of these percentages is a personal forecast. The results describe groups of participants with defined eligibility criteria and research follow-up. The trial used placebo as its comparison. It was not a direct test against Mounjaro or Wegovy.

What about people with type 2 diabetes?

The SYNCHRONIZE-2 trial studied 752 adults with overweight or obesity and type 2 diabetes. At 76 weeks, average weight loss was 8.2% and 9.8% in the survodutide groups, compared with 3.9% with placebo.

The study also measured blood-glucose control. Those findings are relevant to the group studied; they are not instructions to replace diabetes medicines or change insulin doses.

Weight-loss results often differ between populations. It would be wrong to tell someone with diabetes to expect the result from a trial that excluded diabetes. Equally, comparing two separate studies does not establish why one person responds differently from another.

If you have diabetes and are considering weight-management treatment, your current medicines and glucose monitoring need to be part of the discussion. Your diabetes team should know about any proposed change in care.

What survodutide side effects were reported?

Digestive symptoms were common. In SYNCHRONIZE-1, gastrointestinal adverse events were reported by about 81% and 90% of participants in the survodutide groups, compared with about 48% with placebo. They were typically mild to moderate, but that does not mean they were unimportant.

Nausea, vomiting and other digestive symptoms can affect whether someone can continue treatment. A description such as “generally mild” should therefore be read alongside information about people who stop.

The newer cardiovascular trial also reported more digestive symptoms with survodutide. Around one in five participants in its treatment groups stopped because of gastrointestinal events, compared with about 2% on placebo.

These findings do not establish the side-effect risk for every future patient. Trials have particular participants, schedules and monitoring. They do, however, show why tolerability needs to be considered alongside effectiveness.

If you are having side effects from a medicine already prescribed to you, contact your prescriber. Waiting for an experimental treatment is not a substitute for reviewing symptoms that need help now.

Does the new heart-safety result mean it prevents heart attacks?

Not on the basis of this trial alone. The SYNCHRONIZE-CVOT study reported in November 2026 was designed to assess cardiovascular safety in people with obesity and increased cardiovascular risk.

It found that survodutide did not increase the risk of the main combined cardiovascular outcome compared with placebo, within the trial’s prespecified safety assessment. This is reassuring safety evidence.

Showing that a treatment does not raise a defined risk beyond an agreed limit is different from proving that it reduces that risk. The result should not be turned into a promise that survodutide prevents heart attacks or strokes.

The study followed more than 5,500 treated participants, but it still needs to be interpreted alongside the wider evidence. Regulators will need to consider the heart findings alongside weight loss, side effects and how many people stopped treatment before deciding whether the benefits outweigh the risks.

When might survodutide be available in the UK?

There is no routine supply date or prescription price to give here. The treatment remains investigational, and The Care Pharmacy does not supply it.

Zealand Pharma’s November 2026 development update discusses plans for regulatory submissions. Plans to apply are not approval, and an application would still need to be assessed.

UK authorisation, private supply and NHS funding are separate questions. Even if a medicine becomes authorised, its use would depend on the approved indication, individual suitability and the services providing it.

A trial dose should not be copied as a self-treatment schedule. Nor does a website offering a research product establish that it contains the treatment used in the published studies. We cannot recommend sourcing survodutide outside appropriate clinical research.

If you are following the news, look for a clear regulator decision and approved product information before treating a launch claim as established. An expected development milestone is not an appointment or a prescription.

How to consider the treatments available now

You can ask for help with weight management while new medicines are being researched. The NHS overview of overweight and obesity explains the different forms of support, including medicines and specialist services where appropriate.

A consultation should consider your health, current prescriptions and previous treatment. It should also give you a realistic account of side effects, follow-up and what will happen if a medicine is not helping.

For private care, check the ongoing cost and what support is included. Being able to order the next pack is only one part of treatment. You also need to know how to get advice, how progress will be reviewed and when a different approach might be needed.

There is no need to choose a medicine by comparing percentages from unrelated trials. Your prescriber can explain which available options fit your health and what benefit might be realistic for you.

Common questions about survodutide

Is it the same as Mounjaro?

No. Survodutide acts on glucagon and GLP-1 receptors. Tirzepatide, the ingredient in Mounjaro, acts on GIP and GLP-1 receptors. They are different compounds.

Has it only been tested in phase 2?

No. Phase 3 obesity results have been published, including studies in people with and without type 2 diabetes. It remains investigational.

Does a positive phase 3 result guarantee approval?

No. Regulators assess the full evidence for quality, safety and effectiveness. One successful study cannot guarantee the outcome or timing.

Can your consultation prescribe survodutide?

No. The Care Pharmacy does not offer it. Our weight-loss consultation assesses suitability for currently offered prescription treatments.

Find out whether weight-loss treatment is suitable for you

If you would like help choosing a weight-loss treatment, complete our online consultation. Our prescriber will review your health and current medicines to assess whether treatment is suitable.

Start consultation

This guide gives general information. Ask a qualified healthcare professional about your own treatment.

Prescription medicines require a clinical assessment. The clinician may recommend a different treatment or an in-person appointment.

Clinical reviewer

Mohammed Ismail Lakhi, MPharm, is the Superintendent Pharmacist at The Care Pharmacy. He leads clinical governance and is registered with the General Pharmaceutical Council, registration number 2072815.

Medically reviewed by

Mohammed Lakhi

Superintendent Pharmacist

Muhammad Lahki
Mohammed Ismail Lakhi

Ecnoglutide: What Can UK Readers Learn From the Trials?

Ecnoglutide is another name appearing in weight-management research. This guide explains its own trial evidence and the limits of overseas approval.

Read More

Mazdutide: What Does Approval in China Mean for the UK?

A medicine’s approval in one country does not settle its status elsewhere. Here is how to read the mazdutide evidence without confusing the two.

Read More

MariTide: What Do We Know About Amgen’s Treatment?

MariTide and maridebart cafraglutide refer to the same investigational treatment. Here is what its research programme can tell UK readers.

Read More

Petrelintide: What Is This Amylin Treatment?

Petrelintide is an investigational amylin treatment. Read what the studies have measured and why a trial result is different from a treatment recommendation.

Read More

Eloralintide: What Do the Weight-Loss Trials Show?

Eloralintide is being studied as a weight-management treatment. This guide explains the trial findings and the questions they have yet to answer.

Read More

Orforglipron: Eli Lilly’s New Oral GLP-1 Weight Loss Treatment

A new clinical analysis suggests that orforglipron, Eli Lilly’s first GLP-1 weight-loss pill, may become a strong alternative to weekly injections like Wegovy and Mounjaro. The findings come from the latest GLP-1 study 2025, where researchers reported meaningful reductions in body weight, improved blood sugar control, and benefits for adults living with type 2 diabetes […]

Read More
icon
UK-Prescribing Pharmacists
icon
No GP Appointments Needed
icon
Fast & Discreet Delivery